XNCR
Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Xencor Inc (XNCR) until April 19, 2024 and CFO at Xencor Inc (XNCR) until March 31, 2024. Xencor Inc reported in an 8-K filed October 26, 2023 that John Kuch retired as Senior Vice President and Chief Financial Officer, effective March 31, 2024. The proxy statement of Xencor Inc reports total compensation of $4,287,528 for John Kuch in fiscal 2024, including a base salary of $143,591. Disclosed compensation is on record for 5 fiscal years. John Kuch has spoken on 14 earnings calls across 1 company, most recently for Xencor Inc on November 7, 2023. The companies whose calls John Kuch spoke on are classified in the Healthcare sector.
“On October 24, 2023, John Kuch, Senior Vice President and Chief Financial Officer, notified Xencor, Inc. (the "Company") of his intention to retire from the Company effective March 31, 2024.”
“There is – it’s two separate transactions. One is the Ultomiris deal, which there’s caps from $26 million to $28 million, the first $35 million OMERS, we get the excess over that.”
“To address your question, it can be lumpy, the early-stage R&D. I mean, there are preclinical studies but it's not going to be consistently increased quarter-to-quarter to the extent that it was over the previous year.”
“Xencor's broad portfolio of partnerships, collaborations, and licenses continues to generate strong cash flow to support our operations. In 2022, we received $198.7 million in royalties and milestone payments, which helped fund our investments in our portfolio of bispecific and cytokine drug candidates.”
“Xencor's portfolio of collaborations and licenses with partners provides ongoing revenue streams to support investments in our research activities and our expanding pipeline of bispecific and cytokine candidates.”
“Total revenue for the second quarter and the first six months of 2022 was $31 million and $115.6 million, respectively. Revenue for the second quarter and the first half of 2022 was primarily royalty revenue from Vir and Alexion partnerships, related sales of sotrovimab and ULTOMIRIS, respectively.”
Start not stated–2024-03-31
Start not stated–2024-04-19
XNCR
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Xencor Inc (XNCR) | Former Chief Financial Officer | $143,591 | $4,287,528 |
| 2023 | Xencor Inc (XNCR) | Former Chief Financial Officer | $468,000 | $2,233,493 |
| 2022 | Xencor Inc (XNCR) | Former Chief Financial Officer | $450,000 | $2,114,941 |
| 2021 | Xencor Inc (XNCR) | Chief Financial Officer | $415,000 | $1,745,969 |
| 2020 | Xencor Inc (XNCR) | Chief Financial Officer | $400,000 | $1,504,141 |